BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29237758)

  • 1. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis.
    Lagares D; Santos A; Grasberger PE; Liu F; Probst CK; Rahimi RA; Sakai N; Kuehl T; Ryan J; Bhola P; Montero J; Kapoor M; Baron M; Varelas X; Tschumperlin DJ; Letai A; Tager AM
    Sci Transl Med; 2017 Dec; 9(420):. PubMed ID: 29237758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BH3 mimetics as anti-fibrotic therapy: Unleashing the mitochondrial pathway of apoptosis in myofibroblasts.
    Kuehl T; Lagares D
    Matrix Biol; 2018 Aug; 68-69():94-105. PubMed ID: 29408011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis.
    Ilyas SI; Mertens JC; Bronk SF; Hirsova P; Dai H; Roberts LR; Kaufmann SH; Gores GJ
    J Biol Chem; 2014 Aug; 289(33):22835-22849. PubMed ID: 24973208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer.
    Potter DS; Du R; Bhola P; Bueno R; Letai A
    Cell Death Dis; 2021 Jul; 12(8):741. PubMed ID: 34315868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins.
    Renault TT; Elkholi R; Bharti A; Chipuk JE
    J Biol Chem; 2014 Sep; 289(38):26481-26491. PubMed ID: 25096574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET.
    Liu Q; Leber B; Andrews DW
    Cell Cycle; 2012 Oct; 11(19):3536-42. PubMed ID: 22895112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma.
    Park JS; Oh Y; Park YJ; Park O; Yang H; Slania S; Hummers LK; Shah AA; An HT; Jang J; Horton MR; Shin J; Dietz HC; Song E; Na DH; Park EJ; Kim K; Lee KC; Roschke VV; Hanes J; Pomper MG; Lee S
    Nat Commun; 2019 Mar; 10(1):1128. PubMed ID: 30850660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets.
    Kodama T; Takehara T; Hikita H; Shimizu S; Shigekawa M; Li W; Miyagi T; Hosui A; Tatsumi T; Ishida H; Kanto T; Hiramatsu N; Yin XM; Hayashi N
    J Biol Chem; 2011 Apr; 286(16):13905-13. PubMed ID: 21367852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.
    Shahbandi A; Rao SG; Anderson AY; Frey WD; Olayiwola JO; Ungerleider NA; Jackson JG
    Cell Death Differ; 2020 Nov; 27(11):3097-3116. PubMed ID: 32457483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.
    Mertens JC; Fingas CD; Christensen JD; Smoot RL; Bronk SF; Werneburg NW; Gustafson MP; Dietz AB; Roberts LR; Sirica AE; Gores GJ
    Cancer Res; 2013 Jan; 73(2):897-907. PubMed ID: 23221385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
    Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
    Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells.
    Aranovich A; Liu Q; Collins T; Geng F; Dixit S; Leber B; Andrews DW
    Mol Cell; 2012 Mar; 45(6):754-63. PubMed ID: 22464442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases.
    Hinz B; Lagares D
    Nat Rev Rheumatol; 2020 Jan; 16(1):11-31. PubMed ID: 31792399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
    Vandenberg CJ; Cory S
    Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
    Certo M; Del Gaizo Moore V; Nishino M; Wei G; Korsmeyer S; Armstrong SA; Letai A
    Cancer Cell; 2006 May; 9(5):351-65. PubMed ID: 16697956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
    Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
    Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.
    Ritter V; Krautter F; Klein D; Jendrossek V; Rudner J
    Cell Death Dis; 2021 Jul; 12(7):694. PubMed ID: 34257274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.